NRNP 6665 FINAL EXAM 2026/2027 | 300
QUESTIONS AND ANSWERS | VERIFIED 100% |
WALDEN UNIVERSITY
CORE DOMAINS
• Psychiatric Assessment and Diagnostic Reasoning
• Psychopharmacology and Neurobiology
• Mood Disorders Across the Lifespan
• Anxiety, OCD, and Trauma-Related Disorders
• Psychotic Disorders and Schizophrenia Spectrum
• Child and Adolescent Psychiatry
• Geriatric Mental Health
• Psychotherapy Modalities and Therapeutic Interventions
• Legal, Ethical, and Cultural Considerations in PMHNP Practice
• Substance-Related and Impulse-Control Disorders
INTRODUCTION
This comprehensive final examination is designed to evaluate the advanced
clinical knowledge, diagnostic reasoning, and psychopharmacological decision-
making skills required of Psychiatric-Mental Health Nurse Practitioner students at
Walden University. It assesses mastery of psychiatric assessment, DSM-5-TR
diagnostic criteria, differential diagnosis, psychopharmacology, and evidence-
based treatment planning across the lifespan. The exam employs a multiple-choice
format with detailed rationales to simulate real-world clinical scenarios. Emphasis
is placed on critical thinking, patient safety, cultural competence, and the
,integration of psychotherapeutic and psychopharmacologic approaches to deliver
safe, effective, and patient-centered psychiatric care.
SECTION ONE: QUESTIONS 1–300
1. A patient is started on a new psychotropic medication. The PMHNP explains
that steady state is typically reached after approximately how many half-lives?
A. 2 half-lives
B. 3 half-lives
C. 5 half-lives
D. 7 half-lives
RATIONALE: Steady state is achieved when the amount of drug administered
equals the amount eliminated, resulting in plateau blood levels. This typically
takes about five half-lives, regardless of the specific medication. After five half-
lives, approximately 97% of the steady-state concentration is reached.
2. Carbamazepine (Tegretol) is unique among mood stabilizers because it:
A. Has no significant drug interactions
B. Induces its own metabolism over time
C. Does not require serum level monitoring
D. Has a shorter half-life than other mood stabilizers
RATIONALE: Carbamazepine is a known enzyme inducer that induces its own
metabolism (auto-induction). This process lowers its serum level over the first
several weeks of treatment, requiring follow-up level checks and possible dose
adjustments.
3. Fluoxetine (Prozac) has a significantly longer washout period than other SSRIs
primarily because:
A. It has a shorter half-life than other SSRIs
B. Its active metabolite has an extremely long half-life
C. It is not metabolized by the liver
D. It has poor oral bioavailability
RATIONALE: Fluoxetine's active metabolite, norfluoxetine, has a half-life of 7–
,15 days, significantly longer than other SSRIs. This requires a 5-week washout
period before starting an MAOI to prevent serotonin syndrome.
4. The PMHNP is managing a patient on lithium. Lithium typically reaches steady
state after:
A. 3 half-lives
B. 7 days
C. 14 days
D. 5 days
RATIONALE: Lithium follows the same pharmacokinetic principle as other
medications, reaching steady state after approximately five half-lives. Lithium has
a half-life of approximately 24 hours, so steady state is typically achieved in about
5 days.
5. When treating geriatric patients with psychotherapeutic drugs, the PMHNP
must consider that:
A. Elderly persons metabolize drugs more rapidly
B. Elderly persons have decreased renal clearance and increased sensitivity to
medications
C. Standard adult doses are always appropriate
D. Drug interactions are less common
RATIONALE: Aging is associated with decreased hepatic metabolism and renal
clearance, increased body fat, and decreased total body water, all of which
increase drug sensitivity and the risk of toxicity. The principle "start low, go slow"
applies.
6. A 34-year-old reports 2 months of depressed mood, anhedonia, insomnia,
guilt, low energy, poor concentration, and passive thoughts that life is not
worth living. What is the PMHNP's priority next step?
A. Begin an SSRI immediately without further questioning
B. Complete a suicide risk assessment including intent, plan, means, past
behavior, and protective factors
C. Schedule neuropsychological testing
, D. Reassure the patient that passive thoughts are common
RATIONALE: Any suicidal thinking requires a structured safety assessment
before routine treatment planning. The clinician should clarify ideation, intent,
plan, access to means, prior attempts, acute risk factors, and protective factors.
7. A patient with major depressive disorder develops decreased need for sleep,
pressured speech, grandiosity, and risky spending after starting an
antidepressant. Which action is most appropriate?
A. Increase the antidepressant dose
B. Evaluate for a manic episode and reconsider antidepressant monotherapy
C. Add a benzodiazepine and continue unchanged
D. Diagnose ADHD
RATIONALE: New syndromal manic symptoms require evaluation for bipolar
disorder or a medication-associated manic episode. Antidepressant monotherapy
can worsen mood instability in bipolar illness.
8. Which finding most strongly distinguishes delirium from a major
neurocognitive disorder?
A. Memory impairment
B. Older age
C. Acute onset with fluctuating attention and awareness
D. Impaired instrumental activities of daily living
RATIONALE: Delirium is characterized by an acute, fluctuating disturbance in
attention and awareness, often caused by a medical condition, medication,
intoxication, or withdrawal.
9. A 28-year-old male with schizophrenia presents with exacerbated auditory
hallucinations and persecutory delusions after stopping his antipsychotic
medication two weeks ago. Which neurotransmitter abnormality is most
directly associated with his positive symptoms?
A. Decreased serotonin activity in the prefrontal cortex
B. Increased dopamine activity in the mesolimbic pathway
C. Decreased glutamate activity in the mesocortical pathway
QUESTIONS AND ANSWERS | VERIFIED 100% |
WALDEN UNIVERSITY
CORE DOMAINS
• Psychiatric Assessment and Diagnostic Reasoning
• Psychopharmacology and Neurobiology
• Mood Disorders Across the Lifespan
• Anxiety, OCD, and Trauma-Related Disorders
• Psychotic Disorders and Schizophrenia Spectrum
• Child and Adolescent Psychiatry
• Geriatric Mental Health
• Psychotherapy Modalities and Therapeutic Interventions
• Legal, Ethical, and Cultural Considerations in PMHNP Practice
• Substance-Related and Impulse-Control Disorders
INTRODUCTION
This comprehensive final examination is designed to evaluate the advanced
clinical knowledge, diagnostic reasoning, and psychopharmacological decision-
making skills required of Psychiatric-Mental Health Nurse Practitioner students at
Walden University. It assesses mastery of psychiatric assessment, DSM-5-TR
diagnostic criteria, differential diagnosis, psychopharmacology, and evidence-
based treatment planning across the lifespan. The exam employs a multiple-choice
format with detailed rationales to simulate real-world clinical scenarios. Emphasis
is placed on critical thinking, patient safety, cultural competence, and the
,integration of psychotherapeutic and psychopharmacologic approaches to deliver
safe, effective, and patient-centered psychiatric care.
SECTION ONE: QUESTIONS 1–300
1. A patient is started on a new psychotropic medication. The PMHNP explains
that steady state is typically reached after approximately how many half-lives?
A. 2 half-lives
B. 3 half-lives
C. 5 half-lives
D. 7 half-lives
RATIONALE: Steady state is achieved when the amount of drug administered
equals the amount eliminated, resulting in plateau blood levels. This typically
takes about five half-lives, regardless of the specific medication. After five half-
lives, approximately 97% of the steady-state concentration is reached.
2. Carbamazepine (Tegretol) is unique among mood stabilizers because it:
A. Has no significant drug interactions
B. Induces its own metabolism over time
C. Does not require serum level monitoring
D. Has a shorter half-life than other mood stabilizers
RATIONALE: Carbamazepine is a known enzyme inducer that induces its own
metabolism (auto-induction). This process lowers its serum level over the first
several weeks of treatment, requiring follow-up level checks and possible dose
adjustments.
3. Fluoxetine (Prozac) has a significantly longer washout period than other SSRIs
primarily because:
A. It has a shorter half-life than other SSRIs
B. Its active metabolite has an extremely long half-life
C. It is not metabolized by the liver
D. It has poor oral bioavailability
RATIONALE: Fluoxetine's active metabolite, norfluoxetine, has a half-life of 7–
,15 days, significantly longer than other SSRIs. This requires a 5-week washout
period before starting an MAOI to prevent serotonin syndrome.
4. The PMHNP is managing a patient on lithium. Lithium typically reaches steady
state after:
A. 3 half-lives
B. 7 days
C. 14 days
D. 5 days
RATIONALE: Lithium follows the same pharmacokinetic principle as other
medications, reaching steady state after approximately five half-lives. Lithium has
a half-life of approximately 24 hours, so steady state is typically achieved in about
5 days.
5. When treating geriatric patients with psychotherapeutic drugs, the PMHNP
must consider that:
A. Elderly persons metabolize drugs more rapidly
B. Elderly persons have decreased renal clearance and increased sensitivity to
medications
C. Standard adult doses are always appropriate
D. Drug interactions are less common
RATIONALE: Aging is associated with decreased hepatic metabolism and renal
clearance, increased body fat, and decreased total body water, all of which
increase drug sensitivity and the risk of toxicity. The principle "start low, go slow"
applies.
6. A 34-year-old reports 2 months of depressed mood, anhedonia, insomnia,
guilt, low energy, poor concentration, and passive thoughts that life is not
worth living. What is the PMHNP's priority next step?
A. Begin an SSRI immediately without further questioning
B. Complete a suicide risk assessment including intent, plan, means, past
behavior, and protective factors
C. Schedule neuropsychological testing
, D. Reassure the patient that passive thoughts are common
RATIONALE: Any suicidal thinking requires a structured safety assessment
before routine treatment planning. The clinician should clarify ideation, intent,
plan, access to means, prior attempts, acute risk factors, and protective factors.
7. A patient with major depressive disorder develops decreased need for sleep,
pressured speech, grandiosity, and risky spending after starting an
antidepressant. Which action is most appropriate?
A. Increase the antidepressant dose
B. Evaluate for a manic episode and reconsider antidepressant monotherapy
C. Add a benzodiazepine and continue unchanged
D. Diagnose ADHD
RATIONALE: New syndromal manic symptoms require evaluation for bipolar
disorder or a medication-associated manic episode. Antidepressant monotherapy
can worsen mood instability in bipolar illness.
8. Which finding most strongly distinguishes delirium from a major
neurocognitive disorder?
A. Memory impairment
B. Older age
C. Acute onset with fluctuating attention and awareness
D. Impaired instrumental activities of daily living
RATIONALE: Delirium is characterized by an acute, fluctuating disturbance in
attention and awareness, often caused by a medical condition, medication,
intoxication, or withdrawal.
9. A 28-year-old male with schizophrenia presents with exacerbated auditory
hallucinations and persecutory delusions after stopping his antipsychotic
medication two weeks ago. Which neurotransmitter abnormality is most
directly associated with his positive symptoms?
A. Decreased serotonin activity in the prefrontal cortex
B. Increased dopamine activity in the mesolimbic pathway
C. Decreased glutamate activity in the mesocortical pathway
